Nivolumab Plus Cabozantinib Improves Outcomes in Advanced RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nivolumab Plus Cabozantinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
N. Engl. J. Med 2021 Mar 04;384(9)829-841, TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, VM Oyervides Juárez, JJ Hsieh, U Basso, AY Shah, C Suárez, A Hamzaj, JC Goh, C Barrios, M Richardet, C Porta, R Kowalyszyn, JP Feregrino, J Żołnierek, D Pook, ER Kessler, Y Tomita, R Mizuno, J Bedke, J Zhang, MA Maurer, B Simsek, F Ejzykowicz, GM Schwab, AB Apolo, RJ Motzer, CheckMate 9ER InvestigatorsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.